January 20, 2021 -- Akron Biotech and Octapharma have signed an exclusive agreement to produce virally inactivated human AB serum to bring it to the cell therapy market.
Akron will produce human AB serum converted from Octapharma's pooled solvent/detergent treated human plasma product. Together, they aim to enhance the safety of human serum from viruses, such as SARS-CoV-2.
The products will be colabeled and available in the U.S., E.U., and Asia.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
